Allergy clinical trials at UCLA

1 research study open to eligible people

Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
open to eligible people ages 1-3
The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
Los Angeles, California and other locations

Last updated: February 5, 2026